biopharma-reporter7h
Eisai and Biogen launch Alzheimer’s treatment in South Korea
Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s treatment. The drug, designed for early-stage Alzheimer’s patients, is set to ...
biopharma-reporter4d
Amgen announces positive Phase 2 results for its GLP-1-GIP weight loss drug
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
biopharma-reporter4d
Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion
The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...
biopharma-reporter6d
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
biopharma-reporter6d
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
biopharma-reporter6d
We’ve upgraded BioPharmaReporter to give you more of what you love
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...